RxDoctor Payments Data

An Do, MD

Pain Medicine · Lawrenceville, GANPI 1326392648

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,624 of the $7,700 with a category attached, or 86.0%. 24 manufacturers reported payments, led by Medtronic at 42.1% of the total. Reporting peaked in 2019 at $3,372 and has fallen 78.0% since, to $742 in 2025.

$7,700in general payments, 2019–2025

Across 217 payments — averaging $35.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Vertiflex, Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$788
  • Collegium Pharmaceutical, Inc.$355
  • Forte Bio-pharma LLC$337
  • Boston Scientific$259
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$1,07614%
  • Food & beverage$6,62486%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,700 in reported general payments places this provider in the 80th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$252,953
Medicare patients
338
Services billed
2,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl150$100,265
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen704$63,830
Buprenorphine183$47,695
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen662$12,717
Oxycodone Hcl410$6,205
Diclofenac Sodium167$4,093
Gabapentin369$3,387
Pregabalin180$3,073
OxycontinOxycodone Hcl11$2,730
Lidocaine45$2,627
Morphine Sulfate ErMorphine Sulfate102$2,088
Tramadol Hcl279$1,970
Tizanidine Hcl229$1,575
Tramadol Hcl ErTramadol Hcl30$1,480
Doxepin Hcl13$1,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$355$100,265150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →